Cu/Zn superoxide dismutase (SOD1) mutations associated with familial amyotrophic lateral sclerosis (ALS) affect cellular free radical release in the presence of oxidative stress

被引:43
|
作者
Cookson, MR
Menzies, FM
Manning, P
Eggett, CJ
Figlewicz, DA
McNeil, CJ
Shaw, PJ
机构
[1] Univ Sheffield, Sch Med, Dept Neurol, Acad Neurol Unit, Sheffield S10 2RX, S Yorkshire, England
[2] Univ Newcastle Upon Tyne, Dept Clin Biochem, Newcastle Upon Tyne NE1 7RU, Tyne & Wear, England
[3] Univ Rochester, Dept Neurol & Neurobiol & Anat, Rochester, NY 14627 USA
来源
AMYOTROPHIC LATERAL SCLEROSIS AND OTHER MOTOR NEURON DISORDERS | 2002年 / 3卷 / 02期
关键词
amyotrophic lateral sclerosis; SOD1; mutations; nitric oxide; superoxide; neuroprotection;
D O I
10.1080/146608202760196048
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Introduction: The exact molecular mechanisms by which mutations in Cu/Zn superoxide dismutase (SOD1) cause motor neuron injury remain incompletely understood, though a body of evidence suggests that the mutant protein exerts a cell-specific toxic gain of function. The role of nitric oxide (NO) in SOD1-related motor neuron injury has been particularly controversial. Theoretically, there are arguments to suggest that NO may exert an important role in motor neuron injury, but there is relatively little direct experimental support for this hypothesis. Objectives: The present study aimed to examine further the potential role for NO in motor neuron injury caused by mutant SOD1. Method: We have generated a cellular model of familial amyotrophic lateral sclerosis (ALS) by stably transfecting NSC34 cells with one of three mutant forms of SOD1 (G93A, G37R, I113T). In the presence of mutant SOD1, NSC34 cells show increased cell death following oxidative stress induced by serum withdrawal. This model of motor neuron death involves cellular release of superoxide and NO radicals, which were directly measured in real time using microelectrode biosensors. Results: The expression of both normal and mutant SOD1 decreased the measured extracellular superoxide release, but had divergent effects on the measured release of NO. Normal SOD1 increased the measured NO release, whereas cells expressing mutant SOD1 released less NO. Co-administration of two different nitric oxide synthase inhibitors (L-NAME and L-N-methyl arginine) did show some neuroprotective effect, but this was only partial, and the effect was more marked using nuclear integrity as a measure of cell viability, rather than MTT conversion. Cells expressing mutant SOD1 were, however, more sensitive to toxicity induced by extrinsic exposure to NO, using a slow-release NO donor. Conclusion: NO is likely to contribute to motor neuron injury, but this does not fully account for all the cellular toxic effects of mutant SOD1.
引用
收藏
页码:75 / 85
页数:11
相关论文
共 50 条
  • [31] Human Cu/Zn superoxide dismutase (SOD1) overexpression in mice causes mitochondrial vacuolization, axonal degeneration, and premature motoneuron death and accelerates motoneuron disease in mice expressing a familial amyotrophic lateral sclerosis mutant SOD1
    Jaarsma, D
    Haasdijk, ED
    Grashorn, JAC
    Hawkins, R
    van Duijn, W
    Verspaget, HW
    London, J
    Holstege, JC
    NEUROBIOLOGY OF DISEASE, 2000, 7 (06) : 623 - 643
  • [32] Current potential pathogenic mechanisms of copper-zinc superoxide dismutase 1 (SOD1) in amyotrophic lateral sclerosis
    Wang, Xin-Xin
    Chen, Wen-Zhi
    Li, Cheng
    Xu, Ren-Shi
    REVIEWS IN THE NEUROSCIENCES, 2024, 35 (05) : 549 - 563
  • [33] Comprehensive in silico analysis and molecular dynamics of the superoxide dismutase 1 (SOD1) variants related to amyotrophic lateral sclerosis
    Coutinho Pereira, Gabriel Rodrigues
    Abrahim Vieira, Barbara de Azevedo
    De Mesquita, Joelma Freire
    PLOS ONE, 2021, 16 (02):
  • [34] A novel two-base mutation in the Cu/Zn superoxide dismutase gene associated with familial amyotrophic lateral sclerosis in Japan
    Morita, M
    Aoki, M
    Abe, K
    Hasegawa, T
    Sakuma, R
    Onodera, Y
    Ichikawa, N
    Nishizawa, M
    Itoyama, Y
    NEUROSCIENCE LETTERS, 1996, 205 (02) : 79 - 82
  • [35] Marked reduction of the Cu/Zn superoxide dismutase polypeptide in a case of familial amyotrophic lateral sclerosis with the homozygous mutation
    Kato, M
    Aoki, M
    Ohta, M
    Nagai, M
    Ishizaki, F
    Nakamura, S
    Itoyama, Y
    NEUROSCIENCE LETTERS, 2001, 312 (03) : 165 - 168
  • [36] Disruption of the structure of the Golgi apparatus and the function of the secretory pathway by mutants G93A and G85R of Cu, Zn superoxide dismutase (SOD1) of familial amyotrophic lateral sclerosis
    Stieber, A
    Gonatas, JO
    Moore, JS
    Bantly, A
    Yim, HS
    Yim, MB
    Gonatas, NK
    JOURNAL OF THE NEUROLOGICAL SCIENCES, 2004, 219 (1-2) : 45 - 53
  • [37] Engineering a monobody specific to monomeric Cu/Zn-superoxide dismutase associated with amyotrophic lateral sclerosis
    Amesaka, Hiroshi
    Hara, Mizuho
    Sakai, Yuki
    Shintani, Atsuko
    Sue, Kaori
    Yamanaka, Tomoyuki
    Tanaka, Shun-ichi
    Furukawa, Yoshiaki
    PROTEIN SCIENCE, 2024, 33 (04)
  • [38] A Screen to Identify Cellular Modulators of Soluble Levels of an Amyotrophic Lateral Sclerosis (ALS)-Causing Mutant SOD1
    Somalinga, Balajee R.
    Miller, Gregory A.
    Malik, Hiba T.
    Wigley, W. Christian
    Thomas, Philip J.
    JOURNAL OF BIOMOLECULAR SCREENING, 2011, 16 (09) : 974 - 985
  • [39] HtrA2/Omi-immunoreactive intraneuronal inclusions in the anterior horn of patients with sporadic and Cu/Zn superoxide dismutase (SOD1) mutant amyotrophic lateral sclerosis
    Kawamoto, Y.
    Ito, H.
    Kobayashi, Y.
    Suzuki, Y.
    Akiguchi, I.
    Fujimura, H.
    Sakoda, S.
    Kusaka, H.
    Hirano, A.
    Takahashi, R.
    NEUROPATHOLOGY AND APPLIED NEUROBIOLOGY, 2010, 36 (04) : 331 - 344
  • [40] Cu, Zn-superoxide dismutase 1 (SOD1) is a novel target of Puromycin-sensitive aminopeptidase (PSA/NPEPPS): PSA/NPEPPS is a possible modifier of amyotrophic lateral sclerosis
    Ren, Guijie
    Ma, Zhongcai
    Hui, Maria
    Kudo, Lili C.
    Hui, Koon-Sea
    Karsten, Stanislav L.
    MOLECULAR NEURODEGENERATION, 2011, 6